Novartis MF59® vaccine shows strong immune response in A(H1N1) clinical trials
- Details
- Category: Novartis
A pilot trial of Novartis adjuvanted cell culture-based A(H1N1) vaccine[1] indicates that the "swine flu" vaccine elicited a strong immune response and was well tolerated. The trial was run by the UK's University of Leicester and University Hospitals of Leicester.
Abbott to Acquire Visiogen, Expanding Vision Care Portfolio
- Details
- Category: Abbott
Abbott (NYSE: ABT) has announced a definitive agreement to acquire Visiogen, Inc. for $400 million in cash, providing the company with a next-generation accommodating intraocular lens (IOL) technology to address presbyopia for cataract patients.
Bayer Acquires Two Prescription Dermatology Product Lines from SkinMedica in the U.S.
- Details
- Category: Bayer
Intendis GmbH, which is part of Bayer HealthCare, has signed an agreement to acquire two prescription dermatology product lines from SkinMedica, Inc., a dermatology company based in Carlsbad, CA, USA.
Pfizer Concludes Previously Disclosed Settlement Agreement with U.S. Department of Justice
- Details
- Category: Pfizer
Pfizer Inc today announced that it has finalized a previously reported agreement in principle with the U.S. Department of Justice (DOJ) to settle an investigation regarding past off-label promotional practices related to Bextra, which Pfizer voluntarily withdrew from the market in 2005.
New Analysis of the Pfizer-Sponsored TNT Clinical Trial
- Details
- Category: Pfizer
For patients with established heart disease who were treated with a statin, 18 novel biomarkers including C-reactive protein (CRP) did not predict future cardiovascular events such as heart attack and stroke, according to results of an analysis presented today at the 2009 European Society of Cardiology Congress in Barcelona, Spain. By contrast, traditional lipid risk factors were strong predictors of cardiovascular events.
Abbott Launches Next-Generation XIENCE PRIME(TM) Drug Eluting Stent in International Markets
- Details
- Category: Abbott
Abbott (NYSE: ABT) has announced at the European Society of Cardiology Congress the widespread availability of its next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. XIENCE PRIME, which received CE Mark (Conformite Europeenne) in June, offers a novel stent design and a delivery system designed for greater flexibility and enhanced deliverability.
Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks
- Details
- Category: AstraZeneca
AstraZeneca has announced results from the phase III head to head trial, PLATO (A Study of Platelet Inhibition and Patient Outcomes), which demonstrate that ticagrelor (BRILINTA™) has achieved greater efficacy in the primary endpoint, reduction of cardiovascular events (CV death, MI, stroke) over clopidogrel (Plavix®/Iscover®) (9.8% vs. 11.7% at 12 months; 16% RRR; 95% CI, 0.77 to 0.92; p<0.001), without an increase in major bleeding (11.6% vs. 11.2%, p=0.43).
More Pharma News ...
- Bayer Completes Enrollment into Major Phase III Study with Rivaroxaban (ROCKET AF)
- Bayer Completes Enrollment into Major Phase III Study with Rivaroxaban
- Studies Published in The Lancet Show Roflumilast Improves Lung Function and Reduces Exacerbations
- Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test
- Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy
- Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent
- Lilly Reports on Outcome of Phase III Study of Arzoxifene